Literature DB >> 11156376

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

Y Wen1, M C Hu, K Makino, B Spohn, G Bartholomeusz, D H Yan, M C Hung.   

Abstract

HER-2/neu has been implicated in the activation of androgen receptor (AR) and in inducing hormone-independent prostate cancer growth. Here we report that HER-2/neu activates Akt (protein kinase B) to promote prostate cancer cell survival and growth in the absence of androgen. Blocking of the Akt pathway by a dominant-negative Akt or an inhibitor LY294002 abrogates the HER-2/neu-induced AR signaling and cell survival/growth effects in the absence or presence of androgen. Akt specifically binds to AR and phosphorylates serines 213 and 791 of AR. Thus, Akt is a novel activator of AR required for HER-2/neu signaling to androgen-independent survival and growth of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  121 in total

Review 1.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

2.  Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.

Authors:  Milly J McAllister; Pamela McCall; Ashley Dickson; Mark A Underwood; Ditte Andersen; Elizabeth Holmes; Elke Markert; Hing Y Leung; Joanne Edwards
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-01       Impact factor: 5.554

Review 3.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 4.  Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations.

Authors:  Derek N Lavery; Iain J McEwan
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

5.  Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

Authors:  Shang-Ru Wu; Tai-Shan Cheng; Wen-Chi Chen; Hsin-Yi Shyu; Chun-Jung Ko; Hsiang-Po Huang; Chen-Hsin Teng; Chia-Hau Lin; Michael D Johnson; Chen-Yong Lin; Ming-Shyue Lee
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 6.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

Review 7.  Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation.

Authors:  Robert D Ward; Nancy L Weigel
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.

Authors:  Yuexing Zhang; Douglas Linn; Zhenqiu Liu; Jonathan Melamed; Fabio Tavora; Charles Y Young; Angelika M Burger; Anne W Hamburger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.

Authors:  Yin Liu; Jun Qin Mo; Qiande Hu; Gregory Boivin; Linda Levin; Shan Lu; Dianer Yang; Zhongyun Dong; Shan Lu
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.

Authors:  Yu Wang; Todd Romigh; Xin He; Mohammed S Orloff; Robert H Silverman; Warren D Heston; Charis Eng
Journal:  Hum Mol Genet       Date:  2010-08-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.